- In September 2024, Evotec shares jumped 6% after announcing a technology development partnership with Novo Nordisk centered on cell therapy. The collaboration involves funding for development activities in Germany and Italy, along with upfront payments, potential milestone achievements, and royalty incentives. Dr. Cord Dohrmann, Evotec's Chief Scientific Officer, expressed optimism about creating innovative stem cell-based therapies through this partnership
- In September 2024, Tremfya (guselkumab) was FDA-approved for adults with moderately to severely active ulcerative colitis, in addition to its approvals for plaque psoriasis and psoriatic arthritis. It is the first dual-acting interleukin-23 inhibitor for this condition, showing significant remission rates in the QUASAR study. Administered as a 200 mg intravenous induction dose, it follows with subcutaneous maintenance doses of 100 mg every 8 weeks or 200 mg every 4 weeks. This approval highlights Johnson & Johnson's commitment to advancing treatments for inflammatory bowel disease
- In July 2024, Biogen has acquired Human Immunology Biosciences (HI-Bio), enhancing its immunology pipeline with felzartamab, a promising therapeutic candidate. The acquisition will advance felzartamab into Phase 3 trials for various indications. Positive interim results have been reported in Phase 2 studies for IgA nephropathy and antibody-mediated rejection
- In July 2024, Biogen has acquired Human Immunology Biosciences (HI-Bio), enhancing its immunology pipeline with felzartamab, a promising therapeutic candidate. The acquisition will advance felzartamab into Phase 3 trials for various indications. Positive interim results have been reported in Phase 2 studies for IgA nephropathy and antibody-mediated rejection
- In July 2024, AstraZeneca had successfully acquired Amolyt Pharma for up to USD 1.05 billion, enhancing its Alexion Rare Disease pipeline. This includes the Phase III peptide eneboparatide for hypoparathyroidism, expanding AstraZeneca's focus on rare endocrine diseases and calcium regulation treatments
- In June 2024, Aptar Digital Health partnered with SHL Medical to enhance connected device technologies by integrating its SaMD platform. This collaboration aimed to improve the patient experience during self-administration of injectable therapies, supporting better adherence and disease management for patients
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 THERAPEUTICS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET APPLICATION COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 CUSTOMIZATIONS
5 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: REGULATIONS
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION
5.1.1 AUSTRALIA
5.1.2 CHINA
5.1.3 INDIA
5.2 REGULATORY SUBMISSIONS
5.2.1 PRE-SUBMISSION ACTIVITIES
5.2.2 DEVELOPMENT OF TECHNICAL DOCUMENTATION
5.3 CLINICAL EVALUATION
5.4 REGULATORY SUBMISSION PREPARATION
5.5 SUBMISSION TO REGULATORY AUTHORITY
5.6 REVIEW AND EVALUATION BY REGULATORY AUTHORITY
5.7 APPROVAL AND MARKET AUTHORIZATION
5.8 POST-MARKET SURVEILLANCE
5.9 RENEWAL AND COMPLIANCE
5.1 ASEAN MEDICAL DEVICE DIRECTIVE (AMDD)
5.11 ADOPTION OF MIDDLE EAST AND AFRICA STANDARDS (ISO AND IEC)
5.12 COLLABORATION VIA APEC REGULATORY HARMONIZATION STEERING COMMITTEE
5.13 CLINICAL DATA HARMONIZATION
5.14 COMMON TECHNICAL DOCUMENT (CTD) FORMAT
5.15 POST-MARKET SURVEILLANCE AND REPORTING HARMONIZATION
5.16 MUTUAL RECOGNITION AGREEMENTS (MRAS)
5.17 TRAINING AND CAPACITY BUILDING INITIATIVES
5.18 NORTH AMERICA REGULATORY SCENARIO
5.19 MEDICAL DEVICE CLASSIFICATION
5.2 REGULATORY SUBMISSIONS
5.21 EUROPE REGULATORY SCENARIO
5.22 REGULATORY SUBMISSIONS
5.23 MIDDLE EAST AND AFRICA REGULATORY SCENARIO
5.24 SOUTH AMERICA REGULATORY SCENARIO
5.25 INTERNATIONAL HARMONIZATION
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CHRONIC DISEASE
6.1.2 TECHNOLOGICAL ADVANCEMENT IN SELF INJECTIONS
6.1.3 INCREASE IN PATIENT AUTONOMY
6.1.4 RISE IN MOBILE HEALTH APPLICATIONS
6.2 RESTRAINTS
6.2.1 HIGH COST OF SELF INJECTORS
6.2.2 REGULATORY HURDLES AND NEED FOR PROPER TRAINING FOR SELF-INJECTION DEVICES
6.3 OPPORTUNITIES
6.3.1 GOVERNMENT INITIATIVES TO SELF-INJECTIONS
6.3.2 INCREASED RESEARCH AND DEVELOPMENT FOR SELF-INJECTION
6.3.3 GROWING DEMAND FOR BIOLOGICS AND PERSONALIZED MEDICINE
6.4 CHALLENGES
6.4.1 PATIENT RELUCTANCE TOWARDS NEEDLES
6.4.2 ENVIRONMENTAL CONCERNS WITH SELF-INJECTIONS
7 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 SELF-INJECTION DEVICES
7.3 SELF-INJECTION FORMULATION
8 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY DOSAGE FORM
8.1 OVERVIEW
8.2 SINGLE DOSE
8.3 MULTI-DOSE
9 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 SUBCUTANEOUS
9.3 INTRA MUSCULAR
9.4 OTHERS
10 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 AUTOIMMUNE DISEASES
10.3 PAIN MANAGEMENT
10.4 EMERGENCY DRUGS
10.5 ONCOLOGY
10.6 HORMONAL DISORDERS
10.7 OTHERS
11 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 ADULT
11.3 GERIATRIC
11.4 PEDIATRIC
12 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY GENDER
12.1 OVERVIEW
12.2 MALE
12.3 FEMALE
13 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 HOSPITAL PHARMACY
13.4 ONLINE PHARMACY
13.5 OTHERS
14 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY REGION
14.1 MIDDLE EAST AND AFRICA
15 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
16 SWOT ANALYSIS
17 COMPANY PROFILES
17.1 NOVO NORDISK
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 JOHNSON & JOHNSON SERVICES, INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 BIOGEN
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENT
17.4 AMGEN INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 SANOFI
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 ABBVIE INC.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 COMPANY SHARE ANALYSIS
17.6.4 PRODUCT PORTFOLIO
17.6.5 RECENT DEVELOPMENT
17.7 YPSOMED
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 BD
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 ASTRAZENECA
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
17.1 APTARGROUP, INC.
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENTS
17.11 BAYER
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 BAUSCH HEALTH COMPANIES INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.13 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENTS
17.14 CREDENCE MEDSYSTEMS, INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 DALI MEDICAL DEVICES
17.15.1 COMPANY SN.APSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 ENABLE INJECTIONS
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENTS
17.17 E3D ELCAM DRUG DELIVERY DEVICES
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 F. HOFFMANN-LA ROCHE LTD
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
17.19 GSK PLC
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENTS
17.2 GERRESHEIMER AG
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 HASELMEIER
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENT
17.22 IPSEN BIOPHARMACEUTICALS, INC.
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 PRODUCT PORTFOLIO
17.22.4 RECENT DEVELOPMENT
17.23 LILLY
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 MIDAS PHARMA GMBH
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENT
17.25 MERCK & CO., INC.,
17.25.1 COMPANY SNAPSHOT
17.25.2 REVENUE ANALYSIS
17.25.3 PRODUCT PORTFOLIO
17.25.4 RECENT DEVELOPMENT
17.26 NOVARTIS AG
17.26.1 COMPANY SNAPSHOT
17.26.2 REVENUE ANALYSIS
17.26.3 PRODUCT PORTFOLIO
17.26.4 RECENT DEVELOPMENTS
17.27 NEMERA
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENT
17.28 OVAL MEDICAL TECHNOLOGIES LTD. (SMC LIMITED)
17.28.1 COMPANY SNAPSHOT
17.28.2 PRODUCT PORTFOLIO
17.28.3 RECENT DEVELOPMENT
17.29 OWEN MUMFORD
17.29.1 COMPANY SNAPSHOT
17.29.2 PRODUCT PORTFOLIO
17.29.3 RECENT DEVELOPMENT
17.3 PFIZER INC.
17.30.1 COMPANY SNAPSHOT
17.30.2 REVENUE ANALYSIS
17.30.3 PRODUCT PORTFOLIO
17.30.4 RECENT DEVELOPMENT
17.30.5 RECENT DEVELOPMENT
17.31 PHILIP MEDSIZE
17.31.1 COMPANY SNAPSHOT
17.31.2 PRODUCT PORTFOLIO
17.31.3 RECENT DEVELOPMENTS
17.32 PHARMAJET.
17.32.1 COMPANY SNAPSHOT
17.32.2 PRODUCT PORTFOLIO
17.32.3 RECENT DEVELOPMENT
17.33 PENJET
17.33.1 COMPANY SNAPSHOT
17.33.2 1.1.4 PRODUCT PORTFOLIO
17.33.3 RECENT DEVELOPMENT
17.34 RECIPHARM AB
17.34.1 COMPANY SNAPSHOT
17.34.2 PRODUCT PORTFOLIO
17.34.3 RECENT DEVELOPMENTS
17.35 SCHOTT PHARMA
17.35.1 COMPANY SNAPSHOT
17.35.2 PRODUCT PORTFOLIO
17.35.3 RECENT DEVELOPMENTS
17.36 SHL MEDICAL AG
17.36.1 COMPANY SNAPSHOT
17.36.2 PRODUCT PORTFOLIO
17.36.3 RECENT DEVELOPMENT
17.37 SOCIÉTÉ INDUSTRIELLE DE SONCEBOZ SA
17.37.1 COMPANY SNAPSHOT
17.37.2 PRODUCT PORTFOLIO
17.37.3 RECENT DEVELOPMENT
17.38 TERUMO CORPORATION
17.38.1 COMPANY SNAPSHOT
17.38.2 REVENUE ANALYSIS
17.38.3 PRODUCT PORTFOLIO
17.38.4 RECENT DEVELOPMENT
17.39 TAKEDA PHARMACEUTICAL COMPANY LIMITED
17.39.1 COMPANY SNAPSHOT
17.39.2 REVENUE ANALYSIS
17.39.3 PRODUCT PORTFOLIO
17.39.4 RECENT DEVELOPMENT
17.4 TEVA PHARMACEUTICALS
17.40.1 COMPANY SNAPSHOT
17.40.2 REVENUE
17.40.3 PRODUCT PORTFOLIO
17.40.4 RECENT DEVELOPMENT
17.41 UCB PHARMA
17.41.1 COMPANY SNAPSHOT
17.41.2 REVENUE
17.41.3 PRODUCT PORTFOLIO
17.41.4 RECENT DEVELOPMENT
17.42 WEST PHARMACEUTICAL SERVICES
17.42.1 COMPANY SNAPSHOT
17.42.2 REVENUE ANALYSIS
17.42.3 PRODUCT PORTFOLIO
17.42.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 5 MIDDLE EAST AND AFRICA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA SELF-INJECTION FORMULATION IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA SINGLE DOSE IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA MULTI-DOSE IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA SUBCUTANEOUS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA INTRA MUSCULAR IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA OTHERS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA PAIN MANAGEMENT IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA ONCOLOGY IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA OTHERS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA ADULT IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA GERIATRIC IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA PEDIATRIC IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA MALE IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA FEMALE IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA DIRECT TENDER IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA OTHERS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 43 MIDDLE EAST AND AFRICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 44 MIDDLE EAST AND AFRICA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 57 SOUTH AFRICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 58 SOUTH AFRICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 59 SOUTH AFRICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 60 SOUTH AFRICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 61 SOUTH AFRICA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 62 SOUTH AFRICA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 63 SOUTH AFRICA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 64 SOUTH AFRICA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 65 SOUTH AFRICA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 66 SOUTH AFRICA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 67 SOUTH AFRICA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 68 SOUTH AFRICA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 SOUTH AFRICA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 70 SOUTH AFRICA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 71 SOUTH AFRICA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 72 SOUTH AFRICA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 73 SOUTH AFRICA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 74 SAUDI ARABIA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 75 SAUDI ARABIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 76 SAUDI ARABIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 77 SAUDI ARABIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 78 SAUDI ARABIA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 79 SAUDI ARABIA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 80 SAUDI ARABIA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 81 SAUDI ARABIA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 82 SAUDI ARABIA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 83 SAUDI ARABIA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 84 SAUDI ARABIA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 85 SAUDI ARABIA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 86 SAUDI ARABIA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 SAUDI ARABIA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 88 SAUDI ARABIA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 89 SAUDI ARABIA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 90 SAUDI ARABIA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 91 EGYPT SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 92 EGYPT SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 93 EGYPT SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 94 EGYPT SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 95 EGYPT AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 96 EGYPT PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 97 EGYPT WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 EGYPT NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 EGYPT SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 100 EGYPT SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 101 EGYPT SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 102 EGYPT AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 103 EGYPT EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 EGYPT HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 105 EGYPT SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 106 EGYPT SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 107 EGYPT SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 108 U.A.E SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 109 U.A.E SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 110 U.A.E SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 111 U.A.E SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 112 U.A.E AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 113 U.A.E PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 114 U.A.E WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 115 U.A.E NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 U.A.E SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 117 U.A.E SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 118 U.A.E SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 119 U.A.E AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 120 U.A.E EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 121 U.A.E HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 122 U.A.E SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 123 U.A.E SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 124 U.A.E SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 125 ISRAEL SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 126 ISRAEL SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 127 ISRAEL SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 128 ISRAEL SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 129 ISRAEL AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 130 ISRAEL PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 ISRAEL WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 132 ISRAEL NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 133 ISRAEL SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 134 ISRAEL SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 135 ISRAEL SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 136 ISRAEL AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 137 ISRAEL EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 138 ISRAEL HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 139 ISRAEL SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 140 ISRAEL SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 141 ISRAEL SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 142 KUWAIT SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 143 KUWAIT SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 KUWAIT SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 145 KUWAIT SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 146 KUWAIT AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 147 KUWAIT PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 148 KUWAIT WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 149 KUWAIT NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 150 KUWAIT SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 151 KUWAIT SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 152 KUWAIT SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 153 KUWAIT AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 154 KUWAIT EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 155 KUWAIT HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 KUWAIT SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 157 KUWAIT SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 158 KUWAIT SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 159 OMAN SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 160 OMAN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 161 OMAN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 162 OMAN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 163 OMAN AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 164 OMAN PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 165 OMAN WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 166 OMAN NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 167 OMAN SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 168 OMAN SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 169 OMAN SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 170 OMAN AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 171 OMAN EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 172 OMAN HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 173 OMAN SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 174 OMAN SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 175 OMAN SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 176 QATAR SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 177 QATAR SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 178 QATAR SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 179 QATAR SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 180 QATAR AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 181 QATAR PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 182 QATAR WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 183 QATAR NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 184 QATAR SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 185 QATAR SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 186 QATAR SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 187 QATAR AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 188 QATAR EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 189 QATAR HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 190 QATAR SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 191 QATAR SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 192 QATAR SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 193 BAHRAIN SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 194 BAHRAIN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 195 BAHRAIN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 196 BAHRAIN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 197 BAHRAIN AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 198 BAHRAIN PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 199 BAHRAIN WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 200 BAHRAIN NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 201 BAHRAIN SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 202 BAHRAIN SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 203 BAHRAIN SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 204 BAHRAIN AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 205 BAHRAIN EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 206 BAHRAIN HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 207 BAHRAIN SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 208 BAHRAIN SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 209 BAHRAIN SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 210 REST OF MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
List of Figure
FIGURE 1 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 11 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: SEGMENTATION
FIGURE 12 TWO SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 EXECUTIVE SUMMARY
FIGURE 15 SELF-INJECTION DEVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET IN 2024 & 2031
FIGURE 16 DROC ANALYSIS
FIGURE 17 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY PRODUCT TYPE, 2023
FIGURE 18 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION)
FIGURE 19 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY PRODUCT TYPE, CAGR (2024-2031)
FIGURE 20 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY DOSAGE FORM, 2023
FIGURE 22 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY DOSAGE FORM, 2024-2031 (USD MILLION)
FIGURE 23 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY DOSAGE FORM, CAGR (2024-2031)
FIGURE 24 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 25 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 26 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
FIGURE 27 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 28 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 29 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY APPLICATION, 2023
FIGURE 30 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY APPLICATION, 2024-2031 (USD MILLION)
FIGURE 31 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY APPLICATION, CAGR (2024-2031)
FIGURE 32 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 33 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY AGE GROUP, 2023
FIGURE 34 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY AGE GROUP, 2024-2031 (USD MILLION)
FIGURE 35 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 36 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 37 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY GENDER, 2023
FIGURE 38 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY GENDER, 2024-2031 (USD MILLION)
FIGURE 39 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY GENDER, CAGR (2024-2031)
FIGURE 40 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 41 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 42 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 43 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 44 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 45 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: SNAPSHOT (2023)
FIGURE 46 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET: COMPANY SHARE 2023 (%)
